

Supporting Information

Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP

Yi Lin,^a Ernst Wagner,^{*a,b} and Ulrich Lächelt^{*a,b}

^a Department of Pharmacy and Center for NanoScience (CeNS), Ludwig-Maximilians-Universität München, Munich, Germany.

^b Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.

* Corresponding authors: ernst.wagner@lmu.de, ulrich.laechelt@univie.ac.at

Content

| | |
|---|----|
| Table 1. Delivery systems of Cas9 plasmids..... | 2 |
| Table 2. Delivery systems of Cas9 mRNA and sgRNA..... | 6 |
| Table 3. Delivery systems of Cas9 RNPs..... | 8 |
| References..... | 13 |

Table 1. Delivery systems of Cas9 plasmids.

| Type of delivery systems | Main components | Target gene(s) | Target organ(s) or cell types in vivo | Administration route | Ref. |
|----------------------------|--|----------------------|--|-----------------------|------|
| Polymeric delivery systems | Fluorinated branched PEI, RGD-R8-PEG-HA | MTH1 | Tumor | I.V. | 1 |
| | LC09-functionalized PEG-PEI-Cholesterol, LC09-PEG2000-DSPE | VEGFA | Orthotopic osteosarcoma | I.V. | 2 |
| | PEI, HA, and iRGD | Ptpn2 | Tumor | I.V. | 3 |
| | Semiconducting polymer brush, alkyl chains, PEG, and fluorinated PEI | GFP, MTH1 | Tumor | I.T. | 4 |
| | Semiconducting polymer, PEG2000, and PEI | HDR: GFP reporter | Subcutaneous HeLa cells pretreated with pSPN | Ex vivo | 5 |
| | PEI-β-cyclodextrin | RHBDF1, HBB | × | × | 6 |
| | branched PEI | Slc26a4 | × | × | 7 |
| | PEG-PLGA, BHEM-Chol | BCR-ABL | Chronic myeloid leukemia | I.V. | 8 |
| | PEG-PLGA, BHEM-Chol | CD80, CD86, and CD40 | Dendritic cells | I.V. | 9 |
| | PEG-PLGA, BHEM-Chol | Ntn1 | Macrophages, monocytes | I.V. | 10 |
| | PEG5K-PLGA11K, PLGA11K, BHEM-Chol or DOTAP | B220, BAFFR | B cells | I.V. | 11 |
| | PEG-PLGA, PLGA, and BHEM-Chol | NE | Neutrophils | I.V. | 12 |
| | PLGA, chitosan | GFP | × | × | 13 |
| | PLGA, lecithin, DSPE-PEG-cRGD, DSPE-PEG-biotin, DC-cholesterol, and C3F8 filled microbubbles | MGMT | Glioblastoma | I.V. | 14 |
| | Hyperbranched poly(amide-amine)-PBAE, linear PBAE | HPV16 E7 | Tumor | Peritumoral injection | 15 |
| | PBAE | Cdk5 | Tumor | I.T. | 16 |
| | Reducible branched PBAE | GFP | × | × | 17 |
| | PBAE | GFP, iRFP | × | × | 18 |

| | | | | | |
|--------------------------|--|----------------|---|-----------------------------------|----|
| | Cholesterol-terminated ethanolamine-minated PGEA | Fbn1 | Aorta | I.V. in eye canthus vein | 19 |
| | Ethanolamine-modified PGEA, heparin | Survivin | Orthotopic hepatocellular carcinoma | I.V. | 20 |
| | Chitosan, β -galactose-carrying lactobionic acid | VEGFR2 | Tumor | I.V. | 21 |
| | Chitosan-mPEG | x | x | x | 22 |
| | Fluorinated polycations | Survivin | Tumor | I.V. | 23 |
| | PBA-functionalized polyaminoglycosides | Survivin | Tumor | I.V. | 24 |
| | Poly(disulfide)s | CCNE1 | Liver | I.V. | 25 |
| | α -helical polypeptide PPABL _G | Plk1 | Tumor | I.T. | 26 |
| | Lactose-derived branched cationic biopolymer | Survivin | Orthotopic hepatocellular carcinoma | I.V. | 27 |
| | Quaternary ammonium-terminated poly(propylene oxide), Pluronic F127 | HPV E7 | Tumor | I.T. | 28 |
| | Alginate | GFP | x | x | 29 |
| | Pristine 4-arm polyrotaxane, NCAM or PipB peptide | DMD | x | x | 30 |
| Lipidic delivery systems | iLY1809, cholesterol, DSPC, DMG-PEG2K | Plk1 | Tumor | I.T. | 31 |
| | DOTAP, cholesterol, DOPE, PEG2K-C16 ceramide | HPV E6 and E7 | Tumor | I.V. | 32 |
| | DOTAP, cholesterol, DOPE, DSPE-PEG2K, protamine | Plk1 | Tumor | I.T. | 33 |
| | DOTAP, DOPE, DSPE-PEG2K | Knock-in: Idua | Lung, liver and heart (neonatal MPS I mice) | I.V. in superficial temporal vein | 34 |
| | DOTAP, cholesterol, R8-dGR-DSPE-PEG2K | HIF-1 α | Tumor | I.V. | 35 |
| | DOTAP, DOPE, DSPE-PEG2000-NH ₂ or DSPE-PEG2000-pardaxin peptide | CDC6 | Subcutaneous tumor and orthotopic liver tumor | I.V. | 36 |
| | DOTAP, cholesterol, DOPE, Chol-PEG2K or DSPE-PEG2K | GFP | x | x | 37 |
| | Amino lipids | GFP | x | x | 38 |

| | | | | | |
|--|---|----------------------|--------------------------|---|----|
| | Medium chain triglycerides, DOTAP, DOPE, DSPE-PEG2K | Knock-in: Idua | x | x | 39 |
| | DOTAP, TQ-BPN | HPV18 E6 and E7 | Tumor | I.T. | 40 |
| | PC, cholesterol, DOTAP, DSPE-PEG peptide | Hur | x | x | 41 |
| Inorganic and inorganic/ organic hybrid delivery systems | SPION, DOPA-PLys-PEG-Flu, DOPA-PLys-PEG-RVG | BACE1 | Brain | I.V. | 42 |
| | MSN, PAMAM-Apt | EGFR | Hepatocellular carcinoma | I.V. | 43 |
| | Au nanorods, galactose-modified branched PEI | Fas | Liver | I.V. | 44 |
| | Au nanorods, polystyrene sulfonate, β -cyclodextrin-PEI , biguanidyl adamantane | PD-L1 | Tumor | I.T. | 45 |
| | Photocleavable electropositive PEG, UV-emitting upconversion nanoparticles | Plk1 | Tumor | I.T. | 46 |
| | TAT peptide-modified Au nanoparticles, DOTAP, cholesterol, DOPE, DSPE-PEG2K | Plk1 | Tumor | I.T. | 47 |
| | TAT peptide-modified Au nanoclusters, DOTAP, cholesterol, DOPE, DSPE-PEG2K | Plk1 | Tumor | I.T. | 48 |
| | Au nanorods, polystyrene sulfonate, β -cyclodextrin-PEI with or without galactose | Fas | Liver, tumor, muscle | I.V., I.M., peritumoral injection | 49 |
| | Magnetic nanoparticles, PEI | TLR-3 reporter | x | x | 50 |
| | Au nanoclusters, protamine | HPV18 E7 | x | x | 51 |
| | UiO-66, p(HEMA), p(NIPAM) | GFP | x | x | 52 |
| | Cy5.5-MSNs-NLS, poly(dimethyldiallyl ammonium chloride) | Knock-in: GFP-tag | x | x | 53 |
| | MSN, DOTAP, cholesterol, DOPE, DSPE-PEG2K | GFP-RFP reporter | x | Intrastriatal injection | 54 |
| | N-Zn-doped carbon dots | GFP | x | x | 55 |
| | Vitamin D3-functionalized carbon dots | GFP | x | x | 56 |
| | ZIF-C, EGCG | RPSA | x | x | 57 |
| | ErDy nanosheets | Plk1 | Tumor | I.V. | 58 |
| | CaCO ₃ , protamine, AS1411 aptamer and TAT-NLS-HA | CTNNB1 | x | x | 59 |

| | | | | | |
|--------------------------------|--|----------|-------|------------|----|
| | CaCO ₃ , SiO ₂ , poly-L-arginine, dextran sulfate | tdTomato | x | x | 60 |
| | CaCO ₃ , protamine, AS1411 aptamer and NLS-alginate | FAK | x | x | 61 |
| | CaCO ₃ , CaP, protamine, AS1411 aptamer and biotin-carboxymethyl chitosan | CDK11 | x | x | 62 |
| | CaCO ₃ , protamine, AS1411 aptamer and TAT-carboxymethyl chitosan | CTNNB1 | x | x | 63 |
| Bio-derived vesicles | Tumor-derived exosomes | PARP-1 | Tumor | I.V., I.T. | 64 |
| | CAR-EVs | MYC | Tumor | I.V., I.T. | 65 |
| | Exosome-liposome hybrid NPs | CTNNB1 | x | x | 66 |
| Protein-based delivery systems | Protamine, KALA, AS1411 aptamer, carboxymethyl chitosan | CDK11 | x | x | 67 |
| | Histone, KALA, HA, AS1411 aptamer-HA | PPM1D | x | x | 68 |
| | Bispecific antibody derivatives-chromatin | DPH1 | x | x | 69 |
| | HSA, stearyl PEI | PD-L1 | x | x | 70 |

Table 2. Delivery systems of Cas9 mRNA and sgRNA.

| Type of delivery systems | Main components | Target gene(s) | Target organ(s) or cell types in vivo | Administration route | Ref. |
|----------------------------|--|-------------------|--|----------------------|------|
| Polymeric delivery systems | PLGA, DOTAP, DOPE, cholesterol and DSPE-PEG2K | GFP | × | × | 71 |
| | PEG5K-b-PLGA11K, PLGA11K, and BHEM-Chol | CD40 | Dendritic cells | I.V. | 72 |
| | T20-g-PCL, PEI | EGFP | × | × | 73 |
| | PEG-PAsp(DET) | Ai9 reporter | Brain | Intrabrain | 74 |
| | Poly(disulfide)s | CCNE1 | × | × | 25 |
| Lipidic delivery systems | 306O10/cholesterol/DOPE/C14-PEG2K (molar ratio 35/46.5/16/2.5) | LoxP locus | Liver | I.V. | 75 |
| | 306-O12B/cholesterol/DOPC/DMG-PEG2K (molar ratio 50/38.5/10/1.5) | Angptl3 | Liver | I.V. | 76 |
| | Ionizable lipid/cholesterol/DSPC/DMG-PEG/DSPE-PEG (molar ratio 50/10.5/38/1.4/0.1), anti-human EGFR antibody | Plk1 | Tumor (orthotopic glioblastoma and disseminated ovarian tumor) | I.C. and I.P. | 77 |
| | BAMEA-O16B/cholesterol/DOPE/DSPE-PEG2K (weight ratio 16/8/4/1) | Pcsk9 | Liver | I.V. | 78 |
| | 4A3-SC8/cholesterol/DOPE/DMG-PEG (molar ratio 38.5/30/30/1.5) | HDR: BFP to GFP | Tumor | I.V. | 79 |
| | 7C1/cholesterol/18:1 Lyso PC or DOPE/C14-PEG2K (weight ratio 2/0.52/0.28/0.13) | ICAM2 | Splenic endothelial cells and hepatocytes | I.V. | 80 |
| | LP01/cholesterol/DSPC/DMG-PEG2K (molar ratio 45/44/9/2) | Ttr | Liver | I.V. | 81 |
| | 400-O16B-3/cholesterol/DOPE/DSPE-PEG2K (weight ratio 16/4/1/1) | Nrsf | × | × | 82 |
| | 75-OcholB/DOPE (weight ratio 1/1) | EGFP | × | × | 83 |
| | ZA3-Ep10/cholesterol/PEG-lipid (molar ratio 50/38.5/0.5) | LoxP locus | Liver | I.V. | 84 |
| | SORT lipids/5A2-SC8/cholesterol/DOPE/DMG-PEG2K | loxP, PTEN, Pcsk9 | Spleen, liver and lung | I.V. | 85 |
| | 9A1P9/helper lipids/cholesterol/DMG-PEG2K | tdTomato, PTEN | Spleen, liver and lung | I.V. | 86 |
| | C12-200/cholesterol/DOPE/C14-PEG2K/arachidonic acid (weight ratio 50/20/10/10/10) | HDR: Fah | Liver | I.V. | 87 |
| | MPA-A or MPA-Ab/cholesterol/DOPE/DMG-PEG2K (molar ratio 20/40/30/0.75) | EGFP | Tumor | I.V. and I.T. | 88 |

| | | | | | |
|--|--|-----------------|-------|------|----|
| | TT3/cholesterol/DOPE/DMG-PEG2K (molar ratio 15/45/25/0.75) | GFP, Pcsk9 | Liver | I.V. | 89 |
| | PBA-BADP | GFP, HPV18E6 | x | x | 90 |

Table 3. Delivery systems of Cas9 RNPs.

| Type of delivery systems | Main components | Target gene(s) | Target organ(s) or cell types in vivo | Administration route | Ref. |
|----------------------------|---|------------------------------|---|----------------------------|------|
| Polymeric delivery systems | Crosslinked polymer nanocapsule | tdTomato reporter | Murine retinal pigment epithelium and skeletal muscle | Subretinal injection, I.M. | 91 |
| | AD-PAMAM, CD-PEI, AD-PEG, AD-PEG-TAT | DMD | × | × | 92 |
| | Poly(disulfide)s | CCNE1 | × | × | 25 |
| | PEO-b-PDMAEMA-b-PnBMA | mCherry reporter | × | × | 93 |
| | AD-disulfide-guanidyl, β-CD-PEI, microneedle patch | NLRP3 | Subcutaneous keratinocytes and immune cells | Topically on the skin | 94 |
| | PLGA | γ-globin | × | × | 95 |
| | AD and β-CD conjugated PBAP | mCherry | × | × | 96 |
| | Poly(aspartic acid-(2-aminoethyl disulfide)-(4-imidazolecarboxylic acid))-PEG | mCherry | × | × | 97 |
| | AD-PEI, CD-PEI, mHph3 and iRG conjugated DOTAP liposomes | Plk1 | Tumor | I.V. | 98 |
| | Carboxylated branched PBAE | ReNL reporter | Orthotopic glioma tumors | I.C. | 99 |
| | PEI, lecitin, cholesterol, DOGS-NTA(Ni) | DPP-4 | Liver | I.V. | 100 |
| | Boronic acid-rich dendrimer | EGFP, AAVS1, HBB, and CTNNB1 | × | × | 101 |
| | PLys100-CA-mPEG77 | RUNX1, STAT3 | Tumor | I.V. | 102 |
| | NTA-SS-PEG-PCL, iRGD-PEG-pAsp(DAB) | Nrf2 | Tumor | I.V. | 103 |
| | AD-disulfide-guanidyl, β-CD-PEI, HA | mutant KRAS | Tumor and lung | I.V. | 104 |

| | | | | | |
|---|---|------------------|---|--|-----|
| | Polymethacrylates (combinatorial library) | mCherry reporter | x | x | 105 |
| | PEI, lecithin, cholesterol, DOGS-NTA(Ni), anti-EGFR, DPPE | KRAS | Tumor | I.V. | 106 |
| | AD and β -CD conjugated PBAP | mCherry | x | x | 96 |
| | PBAE, HPAE-EB | COL7A1 | x | x | 107 |
| Lipidic delivery systems | Bioreducible lipids/cholesterol/DOPE/C16-PEG2K-ceramide (weight ratio 16/4/1/1) | GFP | x | x | 108 |
| | Bioreducible lipids/cholesterol/DOPE/DSPE-PEG2K (weight ratio 16/4/1/1) | IL1RAP | x | x | 109 |
| | Stemfect RNA transfection reagent | GFP | Tumor | I.T. | 110 |
| | NTA-lipidoid, cholesterol, DOPE, DSPE-PEG2K | GFP | x | x | 111 |
| | Lecithin, cholesterol, DOGS-NTA(Ni), DCP, DSPE-PEG-PDP, DPPE, DPPC | SRD5A2 | Dermal papilla cells in the hair follicle | Topically on the depilated dorsal skin | 112 |
| | A fluorescent surfactant incorporated lipofectamine | GFP | x | x | 113 |
| | RNAiMAX | EGFP, EMX | Inner ear | Injected into mouse cochlea | 114 |
| | Bioreducible lipidoids/cholesterol/DOPE/DSPE-PEG2K (weight ratio 16/4/1/1) | GFP | Liver | I.V. | 115 |
| | 5A2-SC8/cholesterol/zwitterionic lipids/DMG-PEG2K/permanently cationic lipids | Multiple genes | Muscle, brain, liver, lung | I.M., I.V., intrabrain | 116 |
| Inorganic and inorganic/organic hybrid delivery systems | DOTAP/cholesterol/DOPE/verteporfin (molar ratio of 1/1/0.94/0.06) | EGFP | In zebrafish model | Microinjection | 117 |
| | CuS, PEI | Hsp90 α | Tumor | I.T. | 118 |
| | Arginine-modified Au nanoassemblies | PTEN | Spleen, liver (macrophages) | I.V. | 119 |
| | ZIF-8 | GFP | x | x | 120 |
| | Graphene oxide, PEG-PEI | EGFP | x | x | 121 |
| | AD-M12L24 MOC and β -CD-PEI | GFP | x | x | 122 |
| | RNP corona-Au nanoparticles | GFP | x | x | 123 |
| | Arginine-modified Au nanoassemblies | AAVS1, PTEN | x | x | 124 |

| | | | | | |
|--|--|---|---------------|-------------------------------|-----|
| | Black phosphorus nanosheets | Target 1, Grin2b, EGFP | Tumor | I.T. | 125 |
| | TAT-modified Au nanoclusters, DOTAP, cholesterol, DOPE, Gal-PEG-DSPE | Pcsk9 | Liver | I.V. | 126 |
| | ZIF-90 | GFP | × | × | 127 |
| | Cancer cell membrane coated ZIFs | EGFP | × | × | 128 |
| | US-powered Au Nanowires | GFP | × | × | 129 |
| | Au Nanoclusters | E6 | × | × | 130 |
| | MSN, DOTAP, cholesterol, DOPE, DSPE-PEG2K | tdTomato | Brain | Intrastriatal injection | 54 |
| | Au nanoparticles, PEI, PEG | CCR5, γ- globin | × | Ex vivo | 131 |
| | Amine-functionalized mesoporous silica nanoparticles | GFP | × | × | 132 |
| | UCNP@SiO ₂ , PEI | Plk1 | Tumor | I.T. | 133 |
| | Mesoporous silica nanoparticle, DOTAP, cholesterol, DOPE, DSPE-PEG2K | Pcsk9, Apoc3, and Angptl3 | Liver | I.V. | 134 |
| | Bi-functionalized aminoguanidine-PEGylated mesoporous organosilica | GFP | × | × | 135 |
| | TAT and aptamer modified Au nanorods | Plk1 | × | × | 136 |
| | Au nanoparticles, pAsp(DET), thiol-DNA | HDR: DMD | Muscle | I.M. | 137 |
| | N-Zn-doped carbon dots | GFP | × | × | 55 |
| | Au nanorods, PEI, p-AZO, PEG | Hsp90α | Tumor | I.V. | 138 |
| | Silica NPs, PEG, GalNac-PEG | EGFP, Ai14 reporter, HDR: BFP to GFP | Retina, liver | Subretinal injection, I.V. | 139 |
| | PepFect14 | EGFP reporter | × | × | 140 |

| | | | | | |
|---------------------------|--|--|--|-------------------------|-----|
| Peptidic delivery systems | R9 peptide | EGFP, CCR5, ABCC11, EMX1, AAVS1 | x | x | 141 |
| | Supramolecular amphiphilic peptide | EGFP | x | x | 142 |
| | R7L10 peptide | Bace1 | Post-mitotic neurons of the brain | Intrabrain | 143 |
| | Genetic fusion of a supercharged polypeptide | CCR5 | x | x | 144 |
| | Genetic fusion of a supercharged polypeptide | CCR5, AAVS1-AS2 | x | x | 145 |
| | Genetic fusion of a low-molecular-weight protamine | KRAS | Tumor | I.T. | 146 |
| | dNP2 lipopeptide (HypaCas9) | EGFP | x | x | 147 |
| | Shuttle peptide | LoxP site | Lungs (mouse airway epithelia) | Intranasal injection | 148 |
| | Tandem peptide-lipid | GFP reporter | x | x | 149 |
| Bio-derived vesicles | Lipid-containing oligoaminoamides | EGFP | x | x | 150 |
| | Fusogenic glycoprotein decorated vesicles | EGFP | Heart | I.M. | 151 |
| | Nanomembrane-derived extracellular vesicles | DMD | Skeletal muscle | I.M. | 152 |
| | Pseudotyped lentivirus-like particles | B2M, TRAC | x | x | 153 |
| | Engineered murine leukemia virus-like particles | Hpd | HiPSC, HHSC, bone-marrow cells, mouse embryos, liver | Retro-orbital injection | 154 |
| | Gesicles | HIV LTR | x | x | 155 |
| | Extracellular vesicles | DMD exon 53 | Muscle | I.M. | 156 |
| | Tetrahedral DNA nanostructure-extracellular vesicles | WNT10B | Tumor | I.V. | 157 |
| Engineered exosomes | Engineered exosomes | Stop-DsRed reporter | x | x | 158 |

| | | | | | |
|-----------------------------------|---|---|-------|------|-----|
| DNA-based delivery systems | DNA-g-PCL, DNA linker | GFP | x | x | 159 |
| | DNA nanoclew, PEI | GFP | Tumor | I.T. | 160 |
| | DNA nanoflower containing MUC1 aptamers and miR-21 binding sequence | EGFP | Tumor | I.T. | 161 |
| | Branched DNA structure | Plk1 | Tumor | I.V. | 162 |
| Other delivery systems | Cas9 conjugate with asialoglycoprotein receptor ligands (ASGPrL) | EMX1 | x | x | 163 |
| | Folate-targeted CDEH | Plk1 | Tumor | I.T. | 164 |
| | Chitosan-coated RFP, RNP, ssDNA | HDR: BFP to GFP; knock-out: PRDX4 | x | x | 165 |
| | Tetralysine modified H-chain apoferritin (TL-HFn) | GFP | Tumor | I.V. | 166 |
| | Protein-scaffolded CRISPR–Cas9 nanoassembly | EGFP, CD71 | x | x | 167 |

References

1. L. Li, L. Song, X. Liu, X. Yang, X. Li, T. He, N. Wang, S. Yang, C. Yu, T. Yin, Y. Wen, Z. He, X. Wei, W. Su, Q. Wu, S. Yao, C. Gong and Y. Wei, *ACS Nano*, 2017, **11**, 95-111.
2. C. Liang, F. Li, L. Wang, Z.-K. Zhang, C. Wang, B. He, J. Li, Z. Chen, A. B. Shaikh, J. Liu, X. Wu, S. Peng, L. Dang, B. Guo, X. He, D. W. T. Au, C. Lu, H. Zhu, B.-T. Zhang, A. Lu and G. Zhang, *Biomaterials*, 2017, **147**, 68-85.
3. C. Yang, Y. Fu, C. Huang, D. Hu, K. Zhou, Y. Hao, B. Chu, Y. Yang and Z. Qian, *Biomaterials*, 2020, **255**, 120194.
4. L. Li, Z. Yang, S. Zhu, L. He, W. Fan, W. Tang, J. Zou, Z. Shen, M. Zhang, L. Tang, Y. Dai, G. Niu, S. Hu and X. Chen, *Advanced Materials*, 2019, **31**, 1901187.
5. Y. Lyu, S. He, J. Li, Y. Jiang, H. Sun, Y. Miao and K. Pu, *Angewandte Chemie International Edition*, 2019, **58**, 18197-18201.
6. Z. Zhang, T. Wan, Y. Chen, Y. Chen, H. Sun, T. Cao, Z. Songyang, G. Tang, C. Wu, Y. Ping, F.-J. Xu and J. Huang, *Macromolecular Rapid Communications*, 2019, **40**, 1800068.
7. N. Ryu, M.-A. Kim, D. Park, B. Lee, Y.-R. Kim, K.-H. Kim, J.-I. Baek, W. J. Kim, K.-Y. Lee and U.-K. Kim, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2018, **14**, 2095-2102.
8. Y. Liu, G. Zhao, C.-F. Xu, Y.-L. Luo, Z.-D. Lu and J. Wang, *Biomaterials Science*, 2018, **6**, 1592-1603.
9. Y.-L. Luo, L.-F. Liang, Y.-J. Gan, J. Liu, Y. Zhang, Y.-N. Fan, G. Zhao, A. Czarna, Z.-D. Lu, X.-J. Du, S. Shen, C.-F. Xu, Z.-X. Lian and J. Wang, *ACS Applied Materials & Interfaces*, 2020, **12**, 48259-48271.
10. Y.-L. Luo, C.-F. Xu, H.-J. Li, Z.-T. Cao, J. Liu, J.-L. Wang, X.-J. Du, X.-Z. Yang, Z. Gu and J. Wang, *ACS Nano*, 2018, **12**, 994-1005.
11. M. Li, Y.-N. Fan, Z.-Y. Chen, Y.-L. Luo, Y.-C. Wang, Z.-X. Lian, C.-F. Xu and J. Wang, *Nano Research*, 2018, **11**, 6270-6282.
12. Y. Liu, Z.-T. Cao, C.-F. Xu, Z.-D. Lu, Y.-L. Luo and J. Wang, *Biomaterials*, 2018, **172**, 92-104.
13. A. Srivastav, K. Gupta, D. Chakraborty, P. Dandekar and R. Jain, *Journal of Pharmaceutical Innovation*, 2020, DOI: 10.1007/s12247-020-09496-4.
14. Q. Yang, Y. Zhou, J. Chen, N. Huang, Z. Wang and Y. Cheng, *Int J Nanomedicine*, 2021, **16**, 185-199.
15. X. Gao, Z. Jin, X. Tan, C. Zhang, C. Zou, W. Zhang, J. Ding, B. C. Das, K. Severinov, I. I. Hitzeroth, P. R. Debata, D. He, X. Ma, X. Tian, Q. Gao, J. Wu, R. Tian, Z. Cui, W. Fan, Z. Huang, C. Cao, Y. Bao, S. Tan and Z. Hu, *Journal of Controlled Release*, 2020, **321**, 654-668.
16. H. Deng, S. Tan, X. Gao, C. Zou, C. Xu, K. Tu, Q. Song, F. Fan, W. Huang and Z. Zhang, *Acta Pharmaceutica Sinica B*, 2020, **10**, 358-373.
17. Y. Rui, D. R. Wilson, K. Sanders and J. J. Green, *ACS Applied Materials & Interfaces*, 2019, **11**, 10472-10480.
18. Y. Rui, M. Varanasi, S. Mendes, H. M. Yamagata, D. R. Wilson and J. J. Green, *Molecular Therapy - Nucleic Acids*, 2020, **20**, 661-672.
19. X. Zhang, C. Xu, S. Gao, P. Li, Y. Kong, T. Li, Y. Li, F.-J. Xu and J. Du, *Advanced Science*, 2019, **6**, 1900386.
20. J.-J. Nie, Y. Liu, Y. Qi, N. Zhang, B. Yu, D.-F. Chen, M. Yang and F.-J. Xu, *Journal of Controlled Release*, 2021, **333**, 362-373.
21. B.-C. Zhang, P.-Y. Wu, J.-J. Zou, J.-L. Jiang, R.-R. Zhao, B.-Y. Luo, Y.-Q. Liao and J.-W. Shao, *Chemical Engineering Journal*, 2020, **393**, 124688.
22. H. Zhang, T. F. Bahamondez-Canas, Y. Zhang, J. Leal and H. D. C. Smyth, *Molecular Pharmaceutics*, 2018, **15**, 4814-4826.
23. Y. Qi, H. Song, H. Xiao, G. Cheng, B. Yu and F.-J. Xu, *Small*, 2018, **14**, 1803061.
24. M. Shao, Y. Qi, D. Sui and F.-J. Xu, *Biomaterials Science*, 2021, **9**, 7104-7114.

25. J. Guo, T. Wan, B. Li, Q. Pan, H. Xin, Y. Qiu and Y. Ping, *ACS Central Science*, 2021, **7**, 990-1000.
26. H.-X. Wang, Z. Song, Y.-H. Lao, X. Xu, J. Gong, D. Cheng, S. Chakraborty, J. S. Park, M. Li, D. Huang, L. Yin, J. Cheng and K. W. Leong, *Proceedings of the National Academy of Sciences*, 2018, **115**, 4903.
27. Y. Qi, Y. Liu, B. Yu, Y. Hu, N. Zhang, Y. Zheng, M. Yang and F.-J. Xu, *Advanced Science*, 2020, **7**, 2001424.
28. Y.-H. Lao, M. Li, M. A. Gao, D. Shao, C.-W. Chi, D. Huang, S. Chakraborty, T.-C. Ho, W. Jiang, H.-X. Wang, S. Wang and K. W. Leong, *Advanced Science*, 2018, **5**, 1700540.
29. B. Alallam, S. Altahhan, M. Taher, M. H. Mohd Nasir and A. A. Doolaanea, *Pharmaceuticals*, 2020, **13**, 158.
30. M. R. Emami, C. S. Young, Y. Ji, X. Liu, E. Mokhonova, A. D. Pyle, H. Meng and M. J. Spencer, *Advanced Therapeutics*, 2019, **2**, 1900061.
31. C. Li, T. Yang, Y. Weng, M. Zhang, D. Zhao, S. Guo, B. Hu, W. Shao, X. Wang, A. Hussain, X.-J. Liang and Y. Huang, *Bioactive Materials*, 2022, **9**, 590-601.
32. L. Jubair, S. Fallaha and N. A. J. McMillan, *Molecular Therapy*, 2019, **27**, 2091-2099.
33. L. Zhang, P. Wang, Q. Feng, N. Wang, Z. Chen, Y. Huang, W. Zheng and X. Jiang, *NPG Asia Materials*, 2017, **9**, e441-e441.
34. R. S. Schuh, É. Poletto, G. Pasqualim, A. M. V. Tavares, F. S. Meyer, E. A. Gonzalez, R. Giugliani, U. Matte, H. F. Teixeira and G. Baldo, *Journal of Controlled Release*, 2018, **288**, 23-33.
35. M. Li, H. Xie, Y. Liu, C. Xia, X. Cun, Y. Long, X. Chen, M. Deng, R. Guo, Z. Zhang and Q. He, *Journal of Controlled Release*, 2019, **304**, 204-215.
36. H. Yin, X. Yuan, L. Luo, Y. Lu, B. Qin, J. Zhang, Y. Shi, C. Zhu, J. Yang, X. Li, M. Jiang, Z. Luo, X. Shan, D. Chen and J. You, *Advanced Science*, 2020, **7**, 1903381.
37. E. S. Hosseini, M. Nikkhah and S. Hosseinkhani, *Int J Nanomedicine*, 2019, **14**, 4353-4366.
38. D. Sun, Z. Sun, H. Jiang, A. M. Vaidya, R. Xin, N. R. Ayat, A. L. Schilb, P. L. Qiao, Z. Han, A. Naderi and Z.-R. Lu, *Bioconjugate Chemistry*, 2019, **30**, 667-678.
39. R. S. Schuh, T. G. de Carvalho, R. Giugliani, U. Matte, G. Baldo and H. F. Teixeira, *European Journal of Pharmaceutics and Biopharmaceutics*, 2018, **122**, 158-166.
40. X. Li, M. Guo, B. Hou, B. Zheng, Z. Wang, M. Huang, Y. Xu, J. Chang and T. Wang, *Journal of Nanobiotechnology*, 2021, **19**, 231.
41. C.-S. Wang, C.-H. Chang, T.-Y. Tzeng, A. M.-Y. Lin and Y.-L. Lo, *Nanoscale Horizons*, 2021, **6**, 729-743.
42. J. Shen, Z. Lu, J. Wang, Q. Hao, W. Ji, Y. Wu, H. Peng, R. Zhao, J. Yang, Y. Li, Z. Shi and X. Zhang, *Advanced Materials*, 2021, **33**, 2101993.
43. B.-C. Zhang, B.-Y. Luo, J.-J. Zou, P.-Y. Wu, J.-L. Jiang, J.-Q. Le, R.-R. Zhao, L. Chen and J.-W. Shao, *ACS Applied Materials & Interfaces*, 2020, **12**, 57362-57372.
44. Y. Chen, X. Chen, D. Wu, H. Xin, D. Chen, D. Li, H. Pan, C. Zhou and Y. Ping, *Chemistry of Materials*, 2021, **33**, 81-91.
45. H. Tang, X. Xu, Y. Chen, H. Xin, T. Wan, B. Li, H. Pan, D. Li and Y. Ping, *Advanced Materials*, 2021, **33**, 2006003.
46. Y. Wu, J. Zheng, Q. Zeng, T. Zhang and D. Xing, *Nano Research*, 2020, **13**, 2399-2406.
47. P. Wang, L. Zhang, W. Zheng, L. Cong, Z. Guo, Y. Xie, L. Wang, R. Tang, Q. Feng, Y. Hamada, K. Gonda, Z. Hu, X. Wu and X. Jiang, *Angewandte Chemie International Edition*, 2018, **57**, 1491-1496.
48. P. Wang, L. Zhang, Y. Xie, N. Wang, R. Tang, W. Zheng and X. Jiang, *Advanced Science*, 2017, **4**, 1700175.
49. X. Chen, Y. Chen, H. Xin, T. Wan and Y. Ping, *Proceedings of the National Academy of Sciences*, 2020, **117**, 2395.
50. S. S. Rohiwal, N. Dvorakova, J. Klima, M. Vaskovicova, F. Senigl, M. Slouf, E. Pavlova, P. Stepanek, D. Babuka, H. Benes, Z. Ellederova and K. Stieger, *Scientific Reports*, 2020, **10**, 4619.
51. Y. Tao, K. Yi, H. Hu, D. Shao and M. Li, *Journal of Materials Chemistry B*, 2021, **9**, 94-100.

52. N. Rabiee, M. Bagherzadeh, M. Heidarian Haris, A. M. Ghadiri, F. Matloubi Moghaddam, Y. Fatahi, R. Dinarvand, A. Jarahiyan, S. Ahmadi and M. Shokouhimehr, *ACS Applied Materials & Interfaces*, 2021, **13**, 10796-10811.
53. X. Xu, O. Koivisto, C. Liu, J. Zhou, M. Miihkinen, G. Jacquemet, D. Wang, J. M. Rosenholm, Y. Shu and H. Zhang, *Advanced Therapeutics*, 2021, **4**, 2000072.
54. A. Noureddine, A. Maestas-Olguin, E. A. Saada, A. E. LaBauve, J. O. Agola, K. E. Baty, T. Howard, J. K. Sabo, C. R. S. Espinoza, J. A. Doudna, J. S. Schoeniger, K. S. Butler, O. A. Negrete, C. J. Brinker and R. E. Serda, *Acta Biomaterialia*, 2020, **114**, 358-368.
55. A. Hasanzadeh, F. Radmanesh, E. S. Hosseini, I. Hashemzadeh, J. Kiani, H. Nourizadeh, M. Naseri, Y. Fatahi, F. Chegini, Z. Madjd, A. Beyzavi, P. S. Kowalski and M. Karimi, *Bioconjugate Chemistry*, 2021, **32**, 1875-1887.
56. A. Hasanzadeh, F. Radmanesh, E. S. Hosseini, I. Hashemzadeh, J. Kiani, M. Naseri, H. Nourizadeh, Y. Fatahi, B. K. Y. Azar, B. G. Marani, A. Beyzavi, V. P. Mahabadi and M. Karimi, *Nanomedicine*, 2021, **16**, 1673-1690.
57. A. Poddar, S. Pyreddy, F. Carraro, S. Dhakal, A. Rassell, M. R. Field, T. S. Reddy, P. Falcaro, C. M. Doherty and R. Shukla, *Chemical Communications*, 2020, **56**, 15406-15409.
58. Y. L. Balachandran, X. Li and X. Jiang, *Chemical Communications*, 2021, **57**, 9386-9389.
59. X.-Y. He, X.-H. Ren, Y. Peng, J.-P. Zhang, S.-L. Ai, B.-Y. Liu, C. Xu and S.-X. Cheng, *Advanced Materials*, 2020, **32**, 2000208.
60. A. S. Timin, A. R. Muslimov, K. V. Lepik, O. S. Epifanovskaya, A. I. Shakirova, U. Mock, K. Riecken, M. V. Okilova, V. S. Sergeev, B. V. Afanasyev, B. Fehse and G. B. Sukhorukov, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2018, **14**, 97-108.
61. B.-Y. Liu, X.-Y. He, C. Xu, X.-H. Ren, R.-X. Zhuo and S.-X. Cheng, *ACS Applied Materials & Interfaces*, 2019, **11**, 23870-23879.
62. B.-Y. Liu, X.-Y. He, C. Xu, L. Xu, S.-L. Ai, S.-X. Cheng and R.-X. Zhuo, *Biomacromolecules*, 2018, **19**, 2957-2968.
63. X.-Y. He, B.-Y. Liu, Y. Peng, R.-X. Zhuo and S.-X. Cheng, *ACS Applied Materials & Interfaces*, 2019, **11**, 226-237.
64. S. M. Kim, Y. Yang, S. J. Oh, Y. Hong, M. Seo and M. Jang, *Journal of Controlled Release*, 2017, **266**, 8-16.
65. Q. Xu, Z. Zhang, L. Zhao, Y. Qin, H. Cai, Z. Geng, X. Zhu, W. Zhang, Y. Zhang, J. Tan, J. Wang and J. Zhou, *Journal of Controlled Release*, 2020, **326**, 455-467.
66. Y. Lin, J. Wu, W. Gu, Y. Huang, Z. Tong, L. Huang and J. Tan, *Advanced Science*, 2018, **5**, 1700611.
67. B.-Y. Liu, X.-Y. He, R.-X. Zhuo and S.-X. Cheng, *Journal of Controlled Release*, 2018, **291**, 90-98.
68. X.-H. Ren, X.-Y. He, B.-Y. Liu, C. Xu and S.-X. Cheng, *ACS Applied Bio Materials*, 2020, **3**, 7831-7839.
69. T. Killian, A. Buntz, T. Herlet, H. Seul, O. Mundigl, G. Längst and U. Brinkmann, *Nucleic Acids Research*, 2019, **47**, e55-e55.
70. W.-J. Cheng, L.-C. Chen, H.-O. Ho, H.-L. Lin and M.-T. Sheu, *Int J Nanomedicine*, 2018, **13**, 7079-7094.
71. X. Li, Q. Feng, Z. Han and X. Jiang, *Chinese Journal of Chemical Engineering*, 2021, **38**, 216-220.
72. Y. Zhang, S. Shen, G. Zhao, C.-F. Xu, H.-B. Zhang, Y.-L. Luo, Z.-T. Cao, J. Shi, Z.-B. Zhao, Z.-X. Lian and J. Wang, *Biomaterials*, 2019, **217**, 119302.
73. X. Huang, R. Zheng, F. Ding, J. Yang, M. Xie, X. Liu, J. Li, J. Feng, X. Zhu and C. Zhang, *ACS Materials Letters*, 2020, **2**, 1509-1515.
74. S. Abbasi, S. Uchida, K. Toh, T. A. Tockary, A. Dirisala, K. Hayashi, S. Fukushima and K. Kataoka, *Journal of Controlled Release*, 2021, **332**, 260-268.
75. K. A. Hajj, J. R. Melamed, N. Chaudhary, N. G. Lamson, R. L. Ball, S. S. Yerneni and K. A. Whitehead, *Nano Letters*, 2020, **20**, 5167-5175.

76. M. Qiu, Z. Glass, J. Chen, M. Haas, X. Jin, X. Zhao, X. Rui, Z. Ye, Y. Li, F. Zhang and Q. Xu, *Proceedings of the National Academy of Sciences*, 2021, **118**, e2020401118.
77. D. Rosenblum, A. Gutkin, R. Kedmi, S. Ramishetti, N. Veiga, M. Jacobi Ashley, S. Schubert Mollie, D. Friedmann-Morvinski, R. Cohen Zvi, A. Behlke Mark, J. Lieberman and D. Peer, *Science Advances*, **6**, eabc9450.
78. J. Liu, J. Chang, Y. Jiang, X. Meng, T. Sun, L. Mao, Q. Xu and M. Wang, *Advanced Materials*, 2019, **31**, 1902575.
79. L. Farbiak, Q. Cheng, T. Wei, E. Álvarez-Benedicto, L. T. Johnson, S. Lee and D. J. Siegwart, *Advanced Materials*, 2021, **33**, 2006619.
80. C. D. Sago, M. P. Lokugamage, K. Paunovska, D. A. Vanover, C. M. Monaco, N. N. Shah, M. Gamboa Castro, S. E. Anderson, T. G. Rudoltz, G. N. Lando, P. Munnilal Tiwari, J. L. Kirschman, N. Willett, Y. C. Jang, P. J. Santangelo, A. V. Bryksin and J. E. Dahlman, *Proceedings of the National Academy of Sciences*, 2018, **115**, E9944.
81. J. D. Finn, A. R. Smith, M. C. Patel, L. Shaw, M. R. Youniss, J. van Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. R. Shah, A. Shah, D. Ling, J. Growe, M. Pink, E. Rohde, K. M. Wood, W. E. Salomon, W. F. Harrington, C. Dombrowski, W. R. Strapps, Y. Chang and D. V. Morrissey, *Cell Reports*, 2018, **22**, 2227-2235.
82. X. Zhao, Z. Glass, J. Chen, L. Yang, D. L. Kaplan and Q. Xu, *Advanced Healthcare Materials*, 2021, **10**, 2000938.
83. Y. Li, R. Jarvis, K. Zhu, Z. Glass, R. Ogurlu, P. Gao, P. Li, J. Chen, Y. Yu, Y. Yang and Q. Xu, *Angewandte Chemie International Edition*, 2020, **59**, 14957-14964.
84. J. B. Miller, S. Zhang, P. Kos, H. Xiong, K. Zhou, S. S. Perelman, H. Zhu and D. J. Siegwart, *Angewandte Chemie International Edition*, 2017, **56**, 1059-1063.
85. Q. Cheng, T. Wei, L. Farbiak, L. T. Johnson, S. A. Dilliard and D. J. Siegwart, *Nature Nanotechnology*, 2020, **15**, 313-320.
86. S. Liu, Q. Cheng, T. Wei, X. Yu, L. T. Johnson, L. Farbiak and D. J. Siegwart, *Nature Materials*, 2021, **20**, 701-710.
87. H. Yin, C.-Q. Song, J. R. Dorkin, L. J. Zhu, Y. Li, Q. Wu, A. Park, J. Yang, S. Suresh, A. Bizhanova, A. Gupta, M. F. Bolukbasi, S. Walsh, R. L. Bogorad, G. Gao, Z. Weng, Y. Dong, V. Koteliansky, S. A. Wolfe, R. Langer, W. Xue and D. G. Anderson, *Nature Biotechnology*, 2016, **34**, 328-333.
88. X. Zhang, B. Li, X. Luo, W. Zhao, J. Jiang, C. Zhang, M. Gao, X. Chen and Y. Dong, *ACS Applied Materials & Interfaces*, 2017, **9**, 25481-25487.
89. C. Jiang, M. Mei, B. Li, X. Zhu, W. Zu, Y. Tian, Q. Wang, Y. Guo, Y. Dong and X. Tan, *Cell Research*, 2017, **27**, 440-443.
90. Q. Tang, J. Liu, Y. Jiang, M. Zhang, L. Mao and M. Wang, *ACS Applied Materials & Interfaces*, 2019, **11**, 46585-46590.
91. G. Chen, A. A. Abdeen, Y. Wang, P. K. Shahi, S. Robertson, R. Xie, M. Suzuki, B. R. Pattnaik, K. Saha and S. Gong, *Nature Nanotechnology*, 2019, **14**, 974-980.
92. Q. Ban, P. Yang, S.-J. Chou, L. Qiao, H. Xia, J. Xue, F. Wang, X. Xu, N. Sun, R. Y. Zhang, C. Zhang, A. Lee, W. Liu, T.-Y. Lin, Y.-L. Ko, P. Antovski, X. Zhang, S.-H. Chiou, C.-F. Lee, W. Hui, D. Liu, S. J. Jonas, P. S. Weiss and H.-R. Tseng, *Small*, 2021, **17**, 2100546.
93. Z. Tan, Y. Jiang, M. S. Ganewatta, R. Kumar, A. Keith, K. Twaroski, T. Pengo, J. Tolar, T. P. Lodge and T. M. Reineke, *Macromolecules*, 2019, **52**, 8197-8206.
94. T. Wan, Q. Pan and Y. Ping, *Science Advances*, 2021, **7**, eabe2888.
95. L. J. Cruz, T. van Dijk, O. Vepris, T. M. W. Y. Li, T. Schomann, F. Baldazzi, R. Kurita, Y. Nakamura, F. Grosveld, S. Philipsen and C. Eich, *Biomaterials*, 2021, **268**, 120580.
96. Y. Wang, B. Ma, A. A. Abdeen, G. Chen, R. Xie, K. Saha and S. Gong, *ACS Applied Materials & Interfaces*, 2018, **10**, 31915-31927.
97. G. Chen, B. Ma, Y. Wang and S. Gong, *ACS Applied Materials & Interfaces*, 2018, **10**, 18515-18523.
98. Z. Chen, F. Liu, Y. Chen, J. Liu, X. Wang, A. T. Chen, G. Deng, H. Zhang, J. Liu, Z. Hong and J. Zhou, *Advanced Functional Materials*, 2017, **27**, 1703036.
99. Y. Rui, D. R. Wilson, J. Choi, M. Varanasi, K. Sanders, J. Karlsson, M. Lim and J. J. Green, *Science advances*, 2019, **5**, eaay3255.

100. E. Y. Cho, J.-Y. Ryu, H. A. R. Lee, S. H. Hong, H. S. Park, K. S. Hong, S.-G. Park, H. P. Kim and T.-J. Yoon, *Journal of Nanobiotechnology*, 2019, **17**, 19.
101. C. Liu, T. Wan, H. Wang, S. Zhang, Y. Ping and Y. Cheng, *Science advances*, 2019, **5**, eaaw8922.
102. Q. Liu, J. Cai, Y. Zheng, Y. Tan, Y. Wang, Z. Zhang, C. Zheng, Y. Zhao, C. Liu, Y. An, C. Jiang, L. Shi, C. Kang and Y. Liu, *Nano Letters*, 2019, **19**, 7662-7672.
103. S. Deng, X. Li, S. Liu, J. Chen, M. Li, S. Y. Chew, K. W. Leong and D. Cheng, *Science advances*, 2020, **6**, eabb4005.
104. T. Wan, Y. Chen, Q. Pan, X. Xu, Y. Kang, X. Gao, F. Huang, C. Wu and Y. Ping, *Journal of Controlled Release*, 2020, **322**, 236-247.
105. R. Kumar, N. Le, Z. Tan, M. E. Brown, S. Jiang and T. M. Reineke, *ACS Nano*, 2020, **14**, 17626-17639.
106. J.-Y. Ryu, Y. J. Choi, E.-J. Won, E. Hui, H.-S. Kim, Y.-S. Cho and T.-J. Yoon, *Nano Research*, 2020, **13**, 1576-1585.
107. J. O'Keeffe Ahern, I. Lara-Sáez, D. Zhou, R. Murillas, J. Bonafont, Á. Mencía, M. García, D. Manzanares, J. Lynch, R. Foley, Q. Xu, A. Sigen, F. Larcher and W. Wang, *Gene Therapy*, 2021, DOI: 10.1038/s41434-021-00282-6.
108. M. Wang, J. A. Zuris, F. Meng, H. Rees, S. Sun, P. Deng, Y. Han, X. Gao, D. Pouli, Q. Wu, I. Georgakoudi, D. R. Liu and Q. Xu, *Proceedings of the National Academy of Sciences*, 2016, **113**, 2868.
109. T.-C. Ho, H. S. Kim, Y. Chen, Y. Li, M. W. LaMere, C. Chen, H. Wang, J. Gong, C. D. Palumbo, J. M. Ashton, H.-W. Kim, Q. Xu, M. W. Becker and K. W. Leong, *Science Advances*, 2021, **7**, eabg3217.
110. J. S. Ha, J. S. Lee, J. Jeong, H. Kim, J. Byun, S. A. Kim, H. J. Lee, H. S. Chung, J. B. Lee and D.-R. Ahn, *Journal of Controlled Release*, 2017, **250**, 27-35.
111. Y. Li, A. C. Li and Q. Xu, *Advanced Healthcare Materials*, 2019, **8**, 1800996.
112. J.-Y. Ryu, E.-J. Won, H. A. R. Lee, J. H. Kim, E. Hui, H. P. Kim and T.-J. Yoon, *Biomaterials*, 2020, **232**, 119736.
113. J. Li, J. J. Røise, J. Zhang, J. Yang, D. L. Kerr, H. Han and N. Murthy, *Chemical Communications*, 2019, **55**, 4562-4565.
114. J. A. Zuris, D. B. Thompson, Y. Shu, J. P. Guilinger, J. L. Bessen, J. H. Hu, M. L. Maeder, J. K. Joung, Z.-Y. Chen and D. R. Liu, *Nature Biotechnology*, 2015, **33**, 73-80.
115. Y. Li, J. Bolinger, Y. Yu, Z. Glass, N. Shi, L. Yang, M. Wang and Q. Xu, *Biomaterials Science*, 2019, **7**, 596-606.
116. T. Wei, Q. Cheng, Y.-L. Min, E. N. Olson and D. J. Siegwart, *Nature Communications*, 2020, **11**, 3232.
117. Y. A. Aksoy, B. Yang, W. Chen, T. Hung, R. P. Kuchel, N. W. Zammit, S. T. Grey, E. M. Goldys and W. Deng, *ACS Applied Materials & Interfaces*, 2020, **12**, 52433-52444.
118. C. Chen, Y. Ma, S. Du, Y. Wu, P. Shen, T. Yan, X. Li, Y. Song, Z. Zha and X. Han, *Small*, 2021, **17**, 2101155.
119. Y.-W. Lee, R. Mout, D. C. Luther, Y. Liu, L. Castellanos-García, A. S. Burnside, M. Ray, G. Y. Tonga, J. Hardie, H. Nagaraj, R. Das, E. L. Phillips, T. Tay, R. W. Vachet and V. M. Rotello, *Advanced Therapeutics*, 2019, **2**, 1900041.
120. S. K. Alsaiari, S. Patil, M. Alyami, K. O. Alamoudi, F. A. Aleisa, J. S. Merzaban, M. Li and N. M. Khashab, *Journal of the American Chemical Society*, 2018, **140**, 143-146.
121. H. Yue, X. Zhou, M. Cheng and D. Xing, *Nanoscale*, 2018, **10**, 1063-1071.
122. J. Liu, T. Luo, Y. Xue, L. Mao, P. J. Stang and M. Wang, *Angewandte Chemie International Edition*, 2021, **60**, 5429-5435.
123. J. Wu, H. Peng, X. Lu, M. Lai, H. Zhang and X. C. Le, *Angewandte Chemie International Edition*, 2021, **60**, 11104-11109.
124. R. Mout, M. Ray, G. Yesilbag Tonga, Y.-W. Lee, T. Tay, K. Sasaki and V. M. Rotello, *ACS Nano*, 2017, **11**, 2452-2458.

125. W. Zhou, H. Cui, L. Ying and X.-F. Yu, *Angewandte Chemie International Edition*, 2018, **57**, 10268-10272.
126. L. Zhang, L. Wang, Y. Xie, P. Wang, S. Deng, A. Qin, J. Zhang, X. Yu, W. Zheng and X. Jiang, *Angewandte Chemie International Edition*, 2019, **58**, 12404-12408.
127. X. Yang, Q. Tang, Y. Jiang, M. Zhang, M. Wang and L. Mao, *Journal of the American Chemical Society*, 2019, **141**, 3782-3786.
128. M. Z. Alyami, S. K. Alsaiari, Y. Li, S. S. Qutub, F. A. Aleisa, R. Sougrat, J. S. Merzaban and N. M. Khashab, *Journal of the American Chemical Society*, 2020, **142**, 1715-1720.
129. M. Hansen-Bruhn, B. E.-F. de Ávila, M. Beltrán-Gastélum, J. Zhao, D. E. Ramírez-Herrera, P. Angsantikul, K. Vesterager Gothelf, L. Zhang and J. Wang, *Angewandte Chemie International Edition*, 2018, **57**, 2657-2661.
130. E. Ju, T. Li, S. Ramos da Silva and S.-J. Gao, *ACS Applied Materials & Interfaces*, 2019, **11**, 34717-34724.
131. R. Shahbazi, G. Sghia-Hughes, J. L. Reid, S. Kubek, K. G. Haworth, O. Humbert, H.-P. Kiem and J. E. Adair, *Nature Materials*, 2019, **18**, 1124-1132.
132. B. Liu, W. Ejaz, S. Gong, M. Kurbanov, M. Canakci, F. Anson and S. Thayumanavan, *Nano Letters*, 2020, **20**, 4014-4021.
133. Y. Pan, J. Yang, X. Luan, X. Liu, X. Li, J. Yang, T. Huang, L. Sun, Y. Wang, Y. Lin and Y. Song, *Science Advances*, 2019, **5**, eaav7199.
134. J. Gong, H.-X. Wang, Y.-H. Lao, H. Hu, N. Vatan, J. Guo, T.-C. Ho, D. Huang, M. Li, D. Shao and K. W. Leong, *Advanced Materials*, 2020, **32**, 2003537.
135. P. R. Salekdeh, L. Ma'mani, J. Tavakkoly-Bazzaz, H. Mousavi, M. H. Modarressi and G. H. Salekdeh, *Journal of Nanobiotechnology*, 2021, **19**, 95.
136. W. Tang, L. Han, X. Lu, Z. Wang, F. Liu, Y. Li, S. Liu, S. Liu, R. Tian, J. Liu and B. Ding, *ACS Applied Materials & Interfaces*, 2021, **13**, 20974-20981.
137. K. Lee, M. Conboy, H. M. Park, F. Jiang, H. J. Kim, M. A. Dewitt, V. A. Mackley, K. Chang, A. Rao, C. Skinner, T. Shobha, M. Mehdipour, H. Liu, W.-c. Huang, F. Lan, N. L. Bray, S. Li, J. E. Corn, K. Kataoka, J. A. Doudna, I. Conboy and N. Murthy, *Nature Biomedical Engineering*, 2017, **1**, 889-901.
138. X. Li, Y. Pan, C. Chen, Y. Gao, X. Liu, K. Yang, X. Luan, D. Zhou, F. Zeng, X. Han and Y. Song, *Angewandte Chemie International Edition*, 2021, **60**, 21200-21204.
139. Y. Wang, P. K. Shahi, X. Wang, R. Xie, Y. Zhao, M. Wu, S. Roge, B. R. Pattnaik and S. Gong, *Journal of Controlled Release*, 2021, **336**, 296-309.
140. O. Gustafsson, J. Rädler, S. Roudi, T. Lehto, M. Hällbrink, T. Lehto, D. Gupta, S. E. Andaloussi and J. Z. Nordin, *Pharmaceutics*, 2021, **13**, 878.
141. S. Ramakrishna, A.-B. K. Dad, J. Beloork, R. Gopalappa, S.-K. Lee and H. Kim, *Genome research*, 2014, **24**, 1020-1027.
142. I. Lostalé-Seijo, I. Louzao, M. Juanes and J. Montenegro, *Chemical Science*, 2017, **8**, 7923-7931.
143. H. Park, J. Oh, G. Shim, B. Cho, Y. Chang, S. Kim, S. Baek, H. Kim, J. Shin, H. Choi, J. Yoo, J. Kim, W. Jun, M. Lee, C. J. Lengner, Y.-K. Oh and J. Kim, *Nature Neuroscience*, 2019, **22**, 524-528.
144. J. Yin, Q. Wang, S. Hou, L. Bao, W. Yao and X. Gao, *Journal of the American Chemical Society*, 2018, **140**, 17234-17240.
145. J. Yin, S. Hou, Q. Wang, L. Bao, D. Liu, Y. Yue, W. Yao and X. Gao, *Bioconjugate Chemistry*, 2019, **30**, 898-906.
146. S. M. Kim, S. C. Shin, E. E. Kim, S.-H. Kim, K. Park, S. J. Oh and M. Jang, *ACS Nano*, 2018, **12**, 7750-7760.
147. T. T. Thach, D. H. Bae, N. H. Kim, E. S. Kang, B. S. Lee, K. Han, M. Kwak, H. Choi, J. Nam, T. Bae, M. Suh, J. K. Hur and Y. H. Kim, *Small*, 2019, **15**, 1903172.
148. S. Krishnamurthy, C. Wohlford-Lenane, S. Kandimalla, G. Sartre, D. K. Meyerholz, V. Théberge, S. Hallée, A.-M. Duperré, T. Del'Guidice, J.-P. Lepetit-Stoffaës, X. Barbeau, D. Guay and P. B. McCray, *Nature Communications*, 2019, **10**, 4906.
149. P. K. Jain, J. H. Lo, S. Ranawade, M. Downing, A. Panda, M. Tai, S. Raghavan, H. E. Fleming and S. N. Bhatia, *Nanoscale*, 2019, **11**, 21317-21323.
150. J. Kuhn, Y. Lin, A. Krhac Levacic, N. Al Danaf, L. Peng, M. Höhn, D. C. Lamb, E. Wagner and U. Lächelt, *Bioconjugate Chemistry*, 2020, **31**, 729-742.

151. C. Montagna, G. Petris, A. Casini, G. Maule, G. M. Franceschini, I. Zanella, L. Conti, F. Arnoldi, O. R. Burrone, L. Zentilin, S. Zacchigna, M. Giacca and A. Cereseto, *Molecular Therapy - Nucleic Acids*, 2018, **12**, 453-462.
152. P. Gee, M. S. Y. Lung, Y. Okuzaki, N. Sasakawa, T. Iguchi, Y. Makita, H. Hozumi, Y. Miura, L. F. Yang, M. Iwasaki, X. H. Wang, M. A. Waller, N. Shirai, Y. O. Abe, Y. Fujita, K. Watanabe, A. Kagita, K. A. Iwabuchi, M. Yasuda, H. Xu, T. Noda, J. Komano, H. Sakurai, N. Inukai and A. Hotta, *Nature Communications*, 2020, **11**, 1334.
153. J. R. Hamilton, C. A. Tsuchida, D. N. Nguyen, B. R. Shy, E. R. McGarrigle, C. R. Sandoval Espinoza, D. Carr, F. Blaeschke, A. Marson and J. A. Doudna, *Cell Reports*, 2021, **35**, 109207.
154. P. E. Mangeot, V. Risson, F. Fusil, A. Marnef, E. Laurent, J. Blin, V. Mournetas, E. Massouridès, T. J. M. Sohier, A. Corbin, F. Aubé, M. Teixeira, C. Pinset, L. Schaeffer, G. Legube, F.-L. Cosset, E. Verhoeven, T. Ohlmann and E. P. Ricci, *Nature Communications*, 2019, **10**, 45.
155. L. A. Campbell, L. M. Coke, C. T. Richie, L. V. Fortuno, A. Y. Park and B. K. Harvey, *Molecular Therapy*, 2019, **27**, 151-163.
156. X. Yao, P. Lyu, K. Yoo, M. K. Yadav, R. Singh, A. Atala and B. Lu, *Journal of Extracellular Vesicles*, 2021, **10**, e12076.
157. J. Zhuang, J. Tan, C. Wu, J. Zhang, T. Liu, C. Fan, J. Li and Y. Zhang, *Nucleic Acids Research*, 2020, **48**, 8870-8882.
158. Y. Ye, X. Zhang, F. Xie, B. Xu, P. Xie, T. Yang, Q. Shi, C.-Y. Zhang, Y. Zhang, J. Chen, X. Jiang and J. Li, *Biomaterials Science*, 2020, **8**, 2966-2976.
159. F. Ding, X. Huang, X. Gao, M. Xie, G. Pan, Q. Li, J. Song, X. Zhu and C. Zhang, *Nanoscale*, 2019, **11**, 17211-17215.
160. W. Sun, W. Ji, J. M. Hall, Q. Hu, C. Wang, C. L. Beisel and Z. Gu, *Angewandte Chemie International Edition*, 2015, **54**, 12029-12033.
161. J. Shi, X. Yang, Y. Li, D. Wang, W. Liu, Z. Zhang, J. Liu and K. Zhang, *Biomaterials*, 2020, **256**, 120221.
162. J. Liu, T. Wu, X. Lu, X. Wu, S. Liu, S. Zhao, X. Xu and B. Ding, *Journal of the American Chemical Society*, 2019, **141**, 19032-19037.
163. R. Rouet, B. A. Thuma, M. D. Roy, N. G. Lintner, D. M. Rubitski, J. E. Finley, H. M. Wisniewska, R. Mendonsa, A. Hirsh, L. de Oñate, J. Compte Barrón, T. J. McLellan, J. Bellenger, X. Feng, A. Varghese, B. A. Chrunk, K. Borzilleri, K. D. Hesp, K. Zhou, N. Ma, M. Tu, R. Dullea, K. F. McClure, R. C. Wilson, S. Liras, V. Mascitti and J. A. Doudna, *Journal of the American Chemical Society*, 2018, **140**, 6596-6603.
164. X. He, Q. Long, Z. Zeng, L. Yang, Y. Tang and X. Feng, *Advanced Functional Materials*, 2019, **29**, 1906187.
165. J. Qiao, W. Sun, S. Lin, R. Jin, L. Ma and Y. Liu, *Chemical Communications*, 2019, **55**, 4707-4710.
166. X. Pan, X. Pei, H. Huang, N. Su, Z. Wu, Z. Wu and X. Qi, *Journal of Controlled Release*, 2021, **337**, 686-697.
167. X. Zhu, M.-M. Lv, J.-W. Liu, R.-Q. Yu and J.-H. Jiang, *Chemical Communications*, 2019, **55**, 6511-6514.